UroGen Pharma is trading 4.11% down at $43.15, with no clear company-specific announcement explaining the September 10, 2026 decline.
- Scheduled to present at the Cantor Global Healthcare Conference at 2:10 PM ET.
- Broader markets are modestly lower amid hotter wholesale inflation and higher yields.
- Available evidence does not establish a direct catalyst.